Oxford, England, United Kingdom
BMBS & DPhil passionate about translational medicine, with a focus on Haematology and Immunology
Senior Bioinformatician · University of Oxford × Johnson & Johnson Working within the close collaboration of the University of Oxford's Translational Pharmacology and Snelling groups, on bulk, single-cell and spatial multiomics data generated from human immune challenge (HIC) studies — an in vivo approach to understanding immune variance, disease-associated dysregulation, and drug mechanism directly in human tissue. My work spans pipeline development and maintenance for bulk and single RNA-seq and spatial transcriptomics, integration of omics data with clinical and experimental metadata, and application of ML/AI methods to high-dimensional immunology questions. The datasets come primarily from peripheral blood and skin biopsies of human observational and interventional studies, and the science is collaborative across University of Oxford and J&J collaborations. The role sits at the translational end of drug development — bridging academic mechanistic research and early-phase clinical programs for both repurposed and novel therapeutics.
4 year WIMM Prize Studentship-funded DPhil in Medical Sciences at the WIMM MRC Molecular Haematology Unit/University of Oxford in the Vyas lab. The impact of ageing on the human haematopoietic stem cell and memory T cell compartments through the lens of single cell transcriptome analysis • Thesis project aiming to describe the impact of ageing on the cellular composition of the haematopoietic stem cell and memory T cell compartment in human subjects using computational tools to analyse single cell RNA-seq datasets. The descriptive work served as the foundation for devising a machine-learning strategy to substantiate if ageing-associated immune features can stratify COVID-19 patients according to their clinical disease severity using data collected months after the disease’s clinical onset. Side projects included the design of an Illumina NGS - QIAseq - based targeted mutational panel for AML minimal residual disease (MRD) quantification, single cell qRT-PCR validation of single cell RNA-seq gene expression patterns and the analysis of data from NGS projects that served the testing of AML MRD quantification data analysis pipelines and the development of novel targets for acute myeloid leukaemia immune therapies. Thesis submitted on 15th of July 2022 and successfully defended on 6th of September 2022. Leave to supplicate: 21st of October 2022
Working in the Oncological Haematology research group in the team of Assoc .Prof. Dr. Ciprian Tomuleasa on projects regarding CLL, AML, ALL, myelofibrosis and non-Hodgkin lymphomas (cytotoxity, viability, proliferation assays, cell cultures, flow cytometry, working with nanostructures)
Thesis project, funded from an internal grant awarded by my alma mater. Project title: A synthetic lethality approach in the acute myeloid leukaemia chemotherapy: PARP inhibitors plus anthracycline plus decitabine vs anthracycline plus decitabine –in vitro efficacy testing Project duration: 24 consecutive months